OGD2 Pharma;Université de Nantes;Centre National de la Recherche Scientifique CNRS;Institut National de la Santé et de la Recherche Médicale (INSERM);Institut de Cancérologie de l'Ouest (I.C.O)
发明人:
申请号：
EP16002576.3
公开号：
EP3329937A1
申请日:
2016.12.05
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The present disclosure relates to a composition for delivery of an anti-cancer agent into a cell, expressing the OAcGD2 ganglioside comprising:(i) at least one anti-cancer agent, and(ii) at least one antibody recognizing the OAcGD2 ganglioside, wherein the at least one antibody recognizing the OAcGD2 ganglioside enhances the uptake of the at least one anti-cancer agent by the tumor cell. The antibody is known and is named the 8B6 antibody. Several variants of the variable claimed, including consensus sequences. Experimental results are provided for a limited number of anti-cancer agents (topotecan, doxorubicin, temozolomide).Combined therapy with said agents show a more potent anti-tumor efficacy.
